New RSV protections for infants hit cost, insurance hurdles in U.S. rollout
Publishing timestamp: 2023-10-13 12:30:35
Summary
The article discusses two new immunizations, Pfizer's Abrysvo and Sanofi's Beyfortus, that have been approved for use in expectant mothers and infants to protect against respiratory syncytial virus (RSV). However, logistical hurdles such as insurance coverage and the high cost of the immunizations are hindering their rollout. Providers are struggling to obtain information from insurers about coverage, and the steep price is making some providers wary of stocking up without guarantee of payment. These challenges threaten to prevent babies from receiving protection this winter and hinder the launches of both drugs.
Sentiment: MIXED
Keywords: pfizer inc, health insurance, business, business news, sanofi sa, health care industry, pharmaceuticals,